reports hero background
Updated: Nov 21, 2026
IBIO Logo

iBio

NASDAQ:IBIO·Stock Analysis Report
Day Range
$0.76 - $0.83
Market Cap
56.44M
P/E Ratio
0.0000
Avg Value
$2.25
Year Range
$0.68 - $3.82
$0.800$.00 (-0.11%)
1
General Information
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases.

Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

2
iBio (IBIO) Stock Graph
3
How We Grade iBio (IBIO)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade iBio (IBIO) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

5
Peer Ratings

See how iBio compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
BOLDBoundless Bio
N/A
N/A
N/A
N/A
NORDNordicus Partners
N/A
N/A
N/A
N/A
FBIOFortress Biotech
N/A
N/A
N/A
N/A
ONCYOncolytics Biotech
N/A
N/A
N/A
N/A
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
6
Past Performance
How has iBio (IBIO) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

iBio (IBIO) sharpe ratio over the past 5 years is -0.0135 which is considered to be above average compared to the peer average of -0.2419


Benzinga